Business Context and Reporting Period
Company: Achieve Life Sciences, Inc. (ACHV)
Filing Type: Form 8-K (Current Report)
Date of Report: July 25, 2024
Event: Entry into a Material Definitive Agreement (Contingent Convertible Debt Agreement).
Key Financial Metrics and Debt Structure
The filing details a new financing arrangement rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
- Initial Principal Amount: $10.0 million (Term Loan advanced July 25, 2024).
- Additional Availability: Up to $10.0 million in two tranches ($5.0 million each) contingent on specific milestones or lender discretion.
- Interest Rate: Floating rate, greater of 7.0% or Prime Rate minus 1.0%.
- Interest Payment Terms: Interest-only payments until December 31, 2025.
- Maturity Date: December 1, 2027 (extendable to June 1, 2028).
- Collateral: Substantially all assets except intellectual property.
- Refinancing: This agreement fully satisfied and terminated a prior $16.6 million debt agreement.
Material Changes and Conversion Features
The primary material change is the restructuring of debt obligations and the introduction of equity conversion rights.
- Debt Refinancing: Replaced a $16.6 million prior loan with a new $10.0 million initial tranche, with potential for additional funding.
- Initial Conversion Price: $7.00 per share (maximum 1,428,571 shares).
- Subsequent Conversion Price: Greater of $4.854 or 150% of the average closing price (maximum 2,060,156 shares).
- Automatic Conversion Trigger: Occurs if the stock price exceeds $24.00 (for initial tranche) or three times the subsequent conversion price (for later tranches) for 30 consecutive trading days, subject to liquidity conditions.
- Ownership Caps: Conversion is limited to prevent beneficial ownership exceeding 9.99% (19.99% for officers/directors; 4.99% for bank holding companies).
Prepayment and Covenants
- Prepayment Fees: 3.0% if prepaid within the first year; 2.0% in the second year; 1.0% thereafter. Additionally, a 4.0% fee on the original aggregate principal is due upon prepayment.
- Covenants: Includes restrictions on additional indebtedness, liens, dividends, and distributions. The lender is prohibited from short selling or hedging the company's stock.
- Registration Rights: Achieve must register shares issuable upon conversion within 30 days, subject to certain ownership thresholds.
Investor Verification Checklist
- Verify the current cash position and liquidity status to assess the ability to service the new $10.0 million debt and pay monthly interest.
- Confirm the status of the New Drug Application (NDA) for cytisinicline, as the $5.0 million second tranche is contingent on FDA acceptance for filing by October 31, 2025.
- Review the full text of the Debt Agreement (Exhibit 10.1) for specific definitions of "Liquidity Conditions" required for automatic conversion.
- Assess the potential dilution impact if the stock price reaches the $24.00 automatic conversion trigger.
- Monitor the company's compliance with the restrictive covenants regarding dividends and additional indebtedness.